| 
Save the Date:
5th Annual
Cleveland Clinic Innovators Awards Dinner
Tuesday, October 7, 2008
Cleveland Botanical Gardens
5:30 p.m.
Keynote Speaker:
Roger S. Newton, Ph.D.
President and CEO, Esperion Therapeutics, Inc.
 Dr. Newton has worked for over 25 years in the pharmaceutical and life sciences industries. He is currently Founder, President and CEO,
Esperion Therapeutics, Inc., which was divested from Pfizer in May 2008 and restarted as an independent enterprise with $23 million in venture
capital. He was formerly Senior Vice President of Pfizer Global Research and Development and Director, Esperion Therapeutics, a Pfizer Inc.
Company. He was Co-Founder, President and CEO of Esperion Therapeutics, Inc. (NASDAQ:ESPR), a biopharmaceutical company founded in July 1998
and located in Ann Arbor, MI. Esperion was dedicated to the discovery and development of pharmaceutical products for the treatment of
cardiovascular diseases through the use of a new treatment approach called "HDL Therapy". Esperion was acquired by Pfizer in February 2004
for $1.3 billion. Prior to founding Esperion, Dr. Newton was with Warner-Lambert/Parke-Davis (now Pfizer) from 1981-1998. As a Distinguished
Scientist and Chairman of the Atherosclerosis Drug Discovery Team, he co-discovered and was the product champion of what is now the most prescribed
cholesterol reducing drug in the world, atorvastatin (Lipitor®). Dr. Newton's research interests for the past thirty years have focused on the
nutritional and pharmacological regulation of cholesterol and lipoprotein metabolism as they relate to atherosclerosis and vascular diseases.
Dr. Newton is also an Adjunct Associate Professor in the Department of Pharmacology at the University of Michigan Medical School. He has co-authored
nearly one hundred peer-reviewed articles and chapters during his research career. Dr. Newton completed a postdoctoral fellowship in the NIH sponsored
Specialized Center of Research in Atherosclerosis at the University of California, San Diego. He has a Ph.D. in nutrition from the University of
California Davis, a Masters of Science degree in nutritional biochemistry from the University of Connecticut and a Bachelor of Science in biology from
Lafayette College.
Dr. Newton is past Chairman of the Great Lakes Venture Quest, and a former member of the Michigan Life Science Corridor Steering Committee. He is
currently Director on BOD (Board of Directors) of Rubicon Genomics, Resverlogix, Inc., and Ann Arbor Spark, a member of the University of Michigan
Cardiovascular Center and Life Sciences Institute National Advisory Boards, and the University Musical Society Board. Through his philanthropic interests
and the Esperance Family Foundation, he and his family are active supporters of non-profit organizations focusing on human potential, social justice, health
and the environment. He and his wife have three children and live in Ann Arbor, MI.
For more information on past recipients
|
